Skip to content
DataLookout
Menu

NCT07923981

A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B Without Inhibitors

StatusRecruiting
PhasePhase 3
SponsorPfizer
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Annualized Bleeding Rate (ABR) of Treated Bleeding Events
Timeframe: Baseline (up to 12 months prior to informed consent) up to end of 12-month treatment phase

Secondary (47)

Incidence and Severity of Adverse Events and Serious Adverse Events
Incidence and Severity of Thrombotic Events
Incidence and Severity of Thrombotic Microangiopathy
Incidence and Severity of Disseminated Intravascular Coagulation/Consumption Coagulopathy
Incidence and Severity of Injection Site Reactions
Show 42 moreShow less
Incidence of Severe Hypersensitivity Reactions, including Anaphylaxis
Immunogenicity: Incidence of ADA and Clinically Significant Persistent NAb to Marstacimab
ABR of Treated Joint Bleeds
ABR of Treated Spontaneous Bleeds
ABR of Treated Traumatic Bleeds
ABR of Total Bleeds (Treated and Untreated)
Number of Target Joints
ABR of Target Joint Bleeds
ABR of Treated Target Joint Bleeds
Change from Baseline in joint Health as Measured by the Hemophilia Joint Health Score (HJHS)
Change From Baseline in Hemophilia Early Arthropathy Detection With Ultrasound (HEAD-US) Score
Change from Baseline in the Hemophilia Activities List (HAL)
Change from Baseline in the Pediatric Hemophilia Activities List (pedHAL)
Patient Global Impression of Change-Hemophilia (PGIC-H)
Change from Baseline in EuroQoL-5 Dimensions - 5 Levels (EQ-5D-5L)
Change from Baseline in Hemophilia Treatment Experience Measure (Hemo-TEM)
Percentage of Participants With an Overall Treatment Preference for Marstacimab, Prior Hemophilia Therapy, or No Preference, as Assessed by a Treatment Preference Questionnaire
Change From Baseline in Menstrual Bleeding Questionnaire (MBQ)
Pictorial Blood Assessment Chart (PBAC) Score
ABR of Treated Bleeding Events During the Long-Term Extension Phase
ABR of Treated Joint Bleeds During the Long-Term Extension Phase
ABR of Treated Spontaneous Bleeds During the Long-Term Extension Phase
ABR of Treated Traumatic Bleeds During the Long-Term Extension Phase
ABR of Total Bleeds (Treated and Untreated) During the Long-Term Extension Phase
Number of Target Joints During the Long-Term Extension Phase
ABR of Treated Target Joint Bleeds During the Long-Term Extension Phase
Change from Baseline in joint Health as Measured by the Hemophilia Joint Health Score (HJHS) During the Long-Term Extension Phase
Change From Baseline in Hemophilia Early Arthropathy Detection With Ultrasound (HEAD-US) Score During the Long-Term Extension Phase
Incidence and Severity of Adverse Events and Serious Adverse Events During the Long-Term Extension Phase
Incidence and Severity of Thrombotic Events During the Long-Term Extension Phase
Incidence and Severity of Thrombotic Microangiopathy During the Long-Term Extension Phase
Incidence and Severity of Disseminated Intravascular Coagulation/Consumption Coagulopathy During the Long-Term Extension Phase
Incidence and Severity of Injection Site Reactions During the Long-Term Extension Phase
Incidence of Severe Hypersensitivity Reactions, including Anaphylaxis During the Long-Term Extension Phase
Immunogenicity: Incidence of ADA and Clinically Significant Persistent NAb to Marstacimab During the Long-Term Extension Phase
Change from Baseline in the Hemophilia Activities List (HAL) During the Long-Term Extension Phase
Change from Baseline in the Pediatric Hemophilia Activities List (pedHAL) During the Long-Term Extension Phase
Patient Global Impression of Change-Hemophilia (PGIC-H) During the Long-Term Extension Phase
Change from Baseline in EuroQoL-5 Dimensions - 5 Levels (EQ-5D-5L) During the Long-Term Extension Phase
Change from Baseline in Hemophilia Treatment Experience Measure (Hemo-TEM) During the Long-Term Extension Phase
Change From Baseline in Menstrual Bleeding Questionnaire (MBQ) During the Long-Term Extension Phase
Pictorial Blood Assessment Chart (PBAC) Score During the Long-Term Extension Phase

Arms and interventions

marstacimab (PF-06741086)Experimental

All enrolled participants will be assigned to treatment with marstacimab (PF-06741086) administered as once weekly SC injection.

Drugs: marstacimab

Sites

1 site in 1 country

  • Southern Specialty ClinicFlowood, Mississippi, United States